Conformation-specific blockade of the integrin GPIIb/IIIa: A novel antiplatelet strategy that selectively targets activated platelets

Circulation Research

Volumn 99, Issue 1, 2006, Pages 25-33

  Schwarz, Meike ^a   Meade, Gerardene ^b   Stoll, Patrick ^a   Ylanne, Jari ^c   Bassler, Nicole ^d   Chen, Yung Chih ^d   Hagemeyer, Christoph E ^d   Ahrens, Ingo ^a,b   Moran, Niamh ^b   Kenny, Dermot ^b   Fitzgerald, Desmond ^b   Bode, Christoph ^a   Peter, Karlheinz ^d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY OF OULU   (Finland)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Adhesion molecules; GPIIb IIIa; Platelets; Thrombosis

Indexed keywords

EPTIFIBATIDE; TIROFIBAN; VERY LATE ACTIVATION ANTIGEN 2; ANTIBODY; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FERRIC CHLORIDE; FERRIC ION; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; PEPTIDE; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BLEEDING; CAROTID ARTERY; CELL ADHESION; CONTROLLED STUDY; DRUG POTENCY; EVALUATION; FLOW CYTOMETRY; IMMOBILIZED CELL; IMMUNOPRECIPITATION; LIGAND BINDING; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; ANIMAL; BLEEDING TIME; C57BL MOUSE; CAROTID ARTERY DISEASE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; COMPLEMENTARITY DETERMINING REGION; CONFORMATION; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN MOTIF; THROMBOCYTE;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES; BLEEDING TIME; BLOOD PLATELETS; CAROTID ARTERY DISEASES; COMPLEMENTARITY DETERMINING REGIONS; FERRIC COMPOUNDS; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR CONFORMATION; PEPTIDES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS; TYROSINE;

EID: 33746234764     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000232317.84122.0c     Document Type: Article

References (31)

1. Shattil S, Hoxie J, Cunningham M, Brass L. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem. 1985;260:11107-11114.
2. Bennett JS. Structure and function of the platelet integrin alpha(IIb)beta(3). J Clin Invest. 2005;115:3363-3369.
3. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15-28.
4. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost. 2001;86:427-443.
5. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997;80:11B-20B.
6. Vickers S, Theoharides AD, Arison B, Balani SK, Cui D, Duncan CA, Ellis JD, Gorham LM, Polsky SL, Prueksaritanont T, Ramjit HG, Slaughter DE, Vyas KP. In vitro and in vivo studies on the metabolism of tirofiban. Drug Metab Dispos. 1999;27:1360-1366.
7. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation. 2002;106:379-385.
8. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov. 2003;2:703-716.
9. Kereiakes DJ, Berkowitz SD, Lincoff AM, Tcheng JE, Wolski K, Achenbach R, Melsheimer R, Anderson K, Califf RM, Topol EJ. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J. 2000;140:74-80.
10. Madan M, Berkowitz S. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. Am Heart J. 1999;138:317-326.
11. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002;100:2071-2076.
12. Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther. 2004;308:1002-1011.
13. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha- granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res. 2000;45:437-446.
14. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary Syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol. 2000;85:491-493, A10.
15. Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alpha IIbbeta 3) inhibitors. Blood. 1998;92:3240-3249.
16. Racanelli AL, Gibbs SK, Zondlo SC, Seiffert DA, Friedman SM, Feuerstein GZ. Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro. Thromb Res. 2003;110:99-105.
17. Welsh RC, Armstrong PW. A marriage of enhancement: fibrinolysis and conjunctive therapy. Thromb Haemost. 2004;92:1194-1200.
18. Schwarz M, Rottgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, Buttner C, Little M, Bode C, Peter K. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J. 2004;18:1704-1706.
19. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wolle J, Pluckthun A, Virnekas B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol. 2000;296:57-86.
20. Corper AL, Sohi MK, Bonagura VR, Steinitz M, Jefferis R, Feinstein A, Beale D, Taussig MJ, Sutton BJ. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol. 1997;4:374-381.
21. Kleinjung J, Petit MC, Orlewski P, Mamalaki A, Tzartos SJ, Tsikaris V, Sakarellos-Daitsiotis M, Sakarellos C, Marraud M, Cung MT. The third-dimensional structure of the complex between an Fv antibody fragment and an analogue of the main immunogenic region of the acetylcholine receptor: a combined two-dimensional NMR, homology, and molecular modeling approach. Biopolymers. 2000;53:113-128.
22. Longhurst CM, White MM, Wilkinson DA, Jennings LK. A CD9, alphaIIbbeta3, integrin-associated protein, and GPIb/V/IX complex on the surface of human platelets is influenced by alphaIIbbeta3 conformational states. Eur J Biochem. 1999;263:104-111.
23. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005;11:507-514.
24. Savage B, Ruggeri ZM. Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. J Biol Chem. 1991;266:11227-11233.
25. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 2005;130:3-10.
26. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005;115:3355-3362.
27. Fitch JCK, Rollins S, Matis L, Alford B, Aranki S, Collard CD, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O'Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan SK. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999;100:2499-2506.
28. Leath CA 3rd, Douglas JT, Curiel DT, Alvarez RD. Single-chain antibodies: a therapeutic modality for cancer gene therapy (review). Int J Oncol. 2004;24:765-771.
29. Peter K, Graeber J, Kipriyanov S, Zewe-Welschof M, Runge MS, Kubler W, Little M, Bode C. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation. 2000;101:1158-1164.
30. Hagemeyer CE, Tomic I, Weirich U, Graeber J, Nordt T, Runge MS, Bode C, Peter K. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase. J Thromb Haemost. 2004;2:797-803.
31. Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432:59-67.